Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate Essential Hypertension
The aim of this therapeutic observation is to demonstrate the efficacy and safety of telmisartan or telmisartan and HCTZ in the treatment of patients with mild-to-moderate essential hypertension under normal conditions of use after market launch.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||PMS Assessing the Safety and Efficacy of Telmisartan in Patients With Mild-to-moderate Essential Hypertension|
- Primary Endpoints will be the change from baseline in mean systolic blood pressure. [ Time Frame: 4-24 Weeks ] [ Designated as safety issue: No ]
- Secondary Endpoints are clinical control of the BP and response rate. [ Time Frame: 4-24 Weeks ]
- Other secondary Endpoints will be discontinuations and tolerability. [ Time Frame: 4-24 Weeks ]
|Study Start Date:||September 2004|
|Primary Completion Date:||October 2009 (Final data collection date for primary outcome measure)|
|Patients with hypertention|
Study 502.465(NCT00638911) was planned and conducted as 6 independent substudies with varying country participation. One study database, a data management plan or a TSAP were not planned and do not exist which precludes baseline and outcome analyses.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00638911
|Study Chair:||Boehringer Ingelheim||Boehringer Ingelheim|